Resultado da Busca
12 de mar. de 2020 · Deanna Teoh, MD, MS, Fernanda Musa, MD, Ritu Salani, MD, MBA, Warner Huh, MD, and Edward Jimenez, DO. Cervical adenocarcinoma in situ is a unique diagnosis whose management needs to be differentiated from the management of the more prevalent squamous cell dysplasia.
16 de ago. de 2022 · Adenocarcinoma in situ (AIS) of the cervix is a premalignant precursor to cervical adenocarcinoma. The usual interval between clinically detectable AIS and early invasion appears to be at least five years, suggesting ample opportunity for screening and intervention .
RESUMO. O adenocarcinoma cervical é uma patologia grave cuja incidência tem aumentado, principalmente em pacientes jovens. Um diagnóstico oportuno, na assistência pri- mária e secundária à saúde, com métodos convencionais, melhora sobremaneira o prognóstico da paciente, a um custo tolerável para países em desenvolvimento. ABSTRACT.
Definition / general. An intraepithelial lesion containing malignant appearing glandular epithelium that carries a significant risk of invasive adenocarcinoma if not treated. Essential features. Neoplastic glandular precursor for invasive endocervical adenocarcinoma. Variable histologic features based on adenocarcinoma in situ type.
O adenocarcinoma cervical in situ é uma doença rara, totalmente curável, diag-nosticada predominantemente por meio de rastreamento cervicouterino seguido de biópsia guiada por colposcopia e/ou conização.
2 de mar. de 2013 · Cervical adenocarcinoma in situ (AIS) arises in the glandular epithelium of the uterine cervix and is the recognized precursor to invasive adenocarcinoma [1•]. The incidence rate of AIS is much lower compared with cervical intraepithelial neoplasia (CIN) [ 2 ].
This publication represents an extensive literature review with the goal of providing guidelines for the evaluation and management of cervical adenocarcinoma in situ (AIS). The authors drafted the guidelines on behalf of the Society of Gynecologic Oncology, and the guidelines have been reviewed and ….
